Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct;35(10):1727-1730.
doi: 10.1002/mds.28240.

If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?

Grace F Crotty  1   2 , Raymond Y Lo  3 , Michael A Schwarzschild  1   2
Affiliations
Editorial

If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?

Grace F Crotty et al. Mov Disord. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Relevant conflicts of interest/financial disclosures: Nothing to report.

Figures

FIG. 1.
FIG. 1.
Alternative explanations for the inverse association between nonsteroidal anti-inflammatory drugs (NSAIDs) and LRRK2-driven Parkinson’s disease (PD), which may be based on a causal, protective role of NSAIDs (a) or one in which their use is an epiphenomenon (b). Question marks and dashed lines represent uncertain modifiers, mediators, or pathways within each model. Red color represents neuroprotective, inhibitory influences on pathogenicity of LRRK2 mutations on PD.
See this image and copyright information in PMC

Comment on

  • Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.
    San Luciano M, Tanner CM, Meng C, Marras C, Goldman SM, Lang AE, Tolosa E, Schüle B, Langston JW, Brice A, Corvol JC, Goldwurm S, Klein C, Brockman S, Berg D, Brockmann K, Ferreira JJ, Tazir M, Mellick GD, Sue CM, Hasegawa K, Tan EK, Bressman S, Saunders-Pullman R; Michael J. Fox Foundation LRRK2 Cohort Consortium. San Luciano M, et al. Mov Disord. 2020 Oct;35(10):1755-1764. doi: 10.1002/mds.28189. Epub 2020 Jul 14. Mov Disord. 2020. PMID: 32662532 Free PMC article.

References

    1. Luciano MS, Tanner CM, Meng C, et al. Non-steroidal anti-inflammatory use and LRRK2 Parkinson’s disease penetrance. Mov Disord 2020;35(10):1755–1764. - PMC - PubMed
    1. Lee AJ, Wang Y, Alcalay RN, et al. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. Mov Disord 2017;32(10):1432–1438. - PMC - PubMed
    1. Iwaki H, Blauwendraat C, Makarious MB, et al. Penetrance of Parkinson’s disease in LRRK2 p.G2019S carriers is modified by a polygenic risk score. Mov Disord 2020;35(5):774–780. - PMC - PubMed
    1. Bakshi R, Macklin EA, Logan R, et al. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Ann Neurol 2019; 85(4):593–599. - PubMed
    1. Kumar PM, Paing SST, Li H, et al. Differential effect of caffeine intake in subjects with genetic susceptibility to Parkinson’s disease. Sci Rep 2015;5:15492. - PMC - PubMed

Substances